Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 642 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

642 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

642 programs

Clinical programs

Page 9 of 14

  1. SPI-62_DF2

    Lacuna Pharma Pty Ltd

    Cushing's Syndrome

    phase 2 small molecule active

    1 trial

  2. SY-1425, AZACITIDINE

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

    phase 2 small molecule active

    1 trial

  3. SY-1425-202

    Lacuna Pharma Pty Ltd

    RARA-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  4. Sodium chloride Fresenius Kabi 0 for Cerebral Autosomal Dominant Art…

    Lacuna Pharma Pty Ltd

    Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)

    phase 2 small molecule active

    1 trial

  5. Sunvozertinib, Sunvozertinib

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. SynAct-CS003

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

  7. SynAct-CS010

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  8. TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    Taxanes-induced peripheral neuropathy

    phase 2 small molecule active

    1 trial

  9. TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    Capecitabine-induced hand and foot syndrome

    phase 2 small molecule active

    1 trial

  10. TARIAN 007

    Lacuna Pharma Pty Ltd

    EGFR inhibitor-induced folliculitis

    phase 2 small molecule active

    1 trial

  11. TCTLR-101

    Lacuna Pharma Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  12. TEV-48574

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  13. TEV-53408, Placebo to match TEV-53408

    Lacuna Pharma Pty Ltd

    Celiac Disease

    phase 2 small molecule active

    1 trial

  14. TG1-CL-301

    Lacuna Pharma Pty Ltd

    Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

    phase 2 other active

    1 trial

  15. TL-895, TL-895

    Lacuna Pharma Pty Ltd

    B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  16. TL-895-201

    Lacuna Pharma Pty Ltd

    Indolent Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  17. TMP-08012024-3

    Lacuna Pharma Pty Ltd

    Chronic spontaneous urticaria

    phase 2 small molecule active

    1 trial

  18. TMP-18122023-58

    Lacuna Pharma Pty Ltd

    Adults with ADHD and moderate to severe depression

    phase 2 small molecule active

    1 trial

  19. TOP-N53-02

    Lacuna Pharma Pty Ltd

    Digital ulcers in systemic sclerosis

    phase 2 small molecule active

    1 trial

  20. TV48574-IMM-20036

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  21. Terbinafin "Moberg Pharma" for Distal Subungual Onychomycosis

    Lacuna Pharma Pty Ltd

    Distal Subungual Onychomycosis

    phase 2 small molecule active

    1 trial

  22. Tovorafenib, Tovorafenib

    Lacuna Pharma Pty Ltd

    RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients

    phase 2 small molecule active

    1 trial

  23. TransCon CNP, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  24. UP-CLI-2023-01

    Lacuna Pharma Pty Ltd

    to obtain pre-operative mydriasis or for diagnostic purposes

    phase 2 small molecule active

    1 trial

  25. VANCOMYCIN , MaaT013

    Lacuna Pharma Pty Ltd

    Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

    phase 2 small molecule active

    1 trial

  26. VDA-1102, VDA-1102 placebo

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  27. VP-C21-011

    Lacuna Pharma Pty Ltd

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  28. VTX002-201

    Lacuna Pharma Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  29. Vonafexor

    Lacuna Pharma Pty Ltd

    Alport Syndrome

    phase 2 small molecule active

    1 trial

  30. WOE-DE-2023-2

    Lacuna Pharma Pty Ltd

    Diabetic sensorimotor polyneuropathy (DSPN)

    phase 2 small molecule active

    1 trial

  31. ZADAXIN® 1,6 mg/ml

    Lacuna Pharma Pty Ltd

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  32. alpha 1H, Placebo product for Alpha1H

    Lacuna Pharma Pty Ltd

    Non-muscle invasive bladder cancer awaiting transurethral surgery

    phase 2 small molecule active

    1 trial

  33. bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  34. non-preserved sterile liquid formulation

    Lacuna Pharma Pty Ltd

    Type 2 diabetes and Obesity

    phase 2 small molecule active

    1 trial

  35. phosphate buffered saline., FX06

    Lacuna Pharma Pty Ltd

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  36. sotatercept, PL1 - Powder for injection

    Lacuna Pharma Pty Ltd

    Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  37. ​​ENV-202​

    Lacuna Pharma Pty Ltd

    ​​Fragile X Syndrome​

    phase 2 small molecule active

    1 trial

  38. 01API2024

    Lacuna Pharma Pty Ltd

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  39. 01INDA2024

    Lacuna Pharma Pty Ltd

    Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)

    phase 1 other active

    1 trial

  40. 02API2024

    Lacuna Pharma Pty Ltd

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  41. 039(C/a)MD23341

    Lacuna Pharma Pty Ltd

    Intended indication: Major Depressive Disorders with and without anxiety, Healthy volunteers, therapeutic indication not studied

    phase 1 other active

    1 trial

  42. 0439-24

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 1 other active

    1 trial

  43. 1028/25

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  44. 1046/25

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  45. 1048/25

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects).

    phase 1 other active

    1 trial

  46. 1053/25

    Lacuna Pharma Pty Ltd

    Bioequivalence study under fasting conditions

    phase 1 other active

    1 trial

  47. 131I-TLX-101-002

    Lacuna Pharma Pty Ltd

    Glioblastoma multiforme (GBM)

    phase 1 other active

    1 trial

  48. 14-XC-CL

    Lacuna Pharma Pty Ltd

    Parkinson’s Disease

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.